Novichok Nerve Agents: What Science Actually Knows About the Deadliest Weapons

Few classes of chemical weapons have captured public attention as sharply as the A-series nerve agents, widely known as Novichok agents, yet a comprehensive new review in the journal Pharmacia reveals a striking imbalance between notoriety and verified knowledge. These organophosphorus compounds, implicated in the 2018 Salisbury poisoning and the 2020 Navalny case, are generally considered structural relatives of classical nerve agents such as sarin, soman, and VX. But compared with those better-characterized weapons, the A-series remains experimentally shadowy, shaped by restricted access, biosafety concerns, and persistent uncertainty about the exact chemical structures of several compounds attributed to the family. The review, published by researchers synthesizing chemistry, toxicology, detection science, and medical countermeasure research, argues that much of what is popularly assumed about these agents rests on computational predictions and indirect evidence rather than authenticated experimental data.

The chemical story begins in the late Cold War Soviet chemical weapons program, from which most early public-domain information about the A-series originated. Current evidence suggests that many of these compounds belong to the phosphoramidate class of organophosphorus agents, distinguished by phosphorus–nitrogen linkages bearing amidine- or guanidine-like substituents. The most frequently discussed representatives, A-230, A-232, and A-234, have been linked to recent forensic investigations and regulatory actions. Analytical work using high-resolution mass spectrometry, degradation product characterization, and synthetic reference standards has lent increasing support to the proposed structures, yet complete, independently verified structural characterization remains unavailable for a number of compounds. This structural uncertainty is not a trivial detail: several historically proposed structures were reconstructed indirectly from secondary reports, computational analyses, or degradation products, which means toxicological conclusions drawn from them must be interpreted with caution.

What is reasonably well established is the primary molecular mechanism. Like other nerve agents, A-series compounds target acetylcholinesterase, the serine hydrolase that rapidly breaks down the neurotransmitter acetylcholine at cholinergic synapses and neuromuscular junctions. The enzyme’s catalytic machinery, centered on a conserved triad of serine, histidine, and glutamate residues at the base of a narrow aromatic gorge, is disabled when organophosphorus agents covalently modify the catalytic serine. The result is a pathologically stable enzyme adduct, uncontrolled accumulation of acetylcholine, and sustained overstimulation of muscarinic, nicotinic, and central cholinergic receptors. Computational docking studies and limited experimental investigations indicate strong affinity of several proposed A-series structures for the catalytic gorge of human acetylcholinesterase, consistent with their expected extreme toxicity.

Beyond the initial inhibition lies a second, therapeutically critical process known as aging. After phosphylation, the inhibited enzyme can undergo dealkylation or related structural rearrangements that lock the adduct in place and dramatically reduce susceptibility to reactivation by oxime antidotes. Aging is well documented for classical agents, most notoriously soman, whose rapid aging severely narrows the window for treatment. For A-series compounds, several computational studies have predicted rapid or structurally favored aging reactions, and steric shielding around the phosphorus center has been proposed as a mechanism for reduced oxime effectiveness. However, the review emphasizes that direct experimental confirmation of aging kinetics for authentic A-series agents remains scarce, and the widely repeated claim of universal oxime resistance across the family is not currently justified by the evidence.

The clinical picture, extrapolated from classical nerve agent toxicology and the limited case information available, is the cholinergic toxidrome in its full severity. Muscarinic effects include pinpoint pupils, salivation, bronchorrhea, bronchospasm, and bradycardia; nicotinic effects produce muscle fasciculations, progressive weakness, and paralysis; and central involvement can drive seizures, coma, and respiratory depression. Respiratory failure, the principal cause of death, is typically multifactorial, combining brainstem respiratory depression, airway obstruction from secretions, and neuromuscular failure of the diaphragm. Evidence from the Salisbury and Navalny incidents suggests severe poisoning can develop rapidly and demand prolonged intensive care. Prolonged seizure activity also raises the specter of lasting harm, with potential long-term consequences including cognitive impairment and persistent neurological dysfunction, although whether A-series agents carry unique neurotoxic properties beyond those of classical agents remains unresolved.

Medical management follows established nerve agent principles: atropine to block muscarinic receptors, oxime reactivators to restore enzyme activity, benzodiazepines to control seizures, and intensive supportive care. Each tool has limits. Atropine counters secretions and bronchospasm but does nothing to reverse neuromuscular paralysis. Oximes such as pralidoxime, obidoxime, and HI-6 are the only clinically available means of cleaving the phosphyl–enzyme bond, yet experimental studies with A-series-related compounds report variable and sometimes limited reactivation efficiency, possibly due to steric hindrance near the phosphorus center. A further limitation is the poor penetration of current oximes across the blood–brain barrier, meaning central cholinergic toxicity can persist even as peripheral enzyme activity recovers. This gap has fueled development of next-generation reactivators with improved central bioavailability, alongside bioscavenger strategies in which butyrylcholinesterase sequesters the agent before it reaches neuronal targets.

On the detection side, the review highlights a quiet revolution in forensic capability. Because authenticated standards are scarce and the parent compounds degrade quickly, modern investigations increasingly target what the agents leave behind. High-resolution mass spectrometry and Orbitrap-based platforms now enable accurate mass determination, structural elucidation, and nontargeted screening of trace degradation products in complex environmental and biological matrices. Even more powerful is protein adduct analysis: organophosphorus agents react covalently with nucleophilic residues in blood proteins, generating stable biomarkers that persist for days or weeks after exposure. Adducts on butyrylcholinesterase are regarded as among the most reliable retrospective markers, with albumin adducts extending the detection window further. These techniques, coupled with isotope-pattern analysis and retrospective data mining, have become central to the forensic work of the international laboratory networks coordinated through the Organisation for the Prohibition of Chemical Weapons, which added several A-series-related compounds and precursors to Schedule 1 of the Chemical Weapons Convention in amendments adopted in 2019.

Environmental behavior remains one of the murkiest areas. Some A-series compounds are proposed to be more environmentally persistent than classical agents, owing to steric shielding that slows spontaneous hydrolysis, but the review cautions that generalized claims of exceptional stability rest on few studies, many involving surrogate compounds. Hydrolysis generates phosphorus-containing degradation products that can remain analytically detectable after the parent agent disappears, aiding attribution, yet degradation kinetics and the toxicological significance of secondary products are poorly mapped. Decontamination protocols, from prompt clothing removal and washing to alkaline hydrolysis and oxidative degradation, are expected to be broadly effective, but few studies have systematically validated them against authenticated A-series agents under realistic conditions.

Computational toxicology has partly filled the experimental void. Molecular docking, molecular dynamics simulations, density functional theory calculations, and quantitative structure–activity relationship models have been used to predict potency, aging pathways, and environmental properties, while machine-learning algorithms are increasingly applied to toxicity prediction, biomarker discovery, and the interpretation of complex mass spectrometric datasets. The review’s verdict on these tools is measured: they generate valuable mechanistic hypotheses, but most predictions remain insufficiently validated by experiment, and model extrapolation is constrained by the small number of authenticated compounds that have been characterized.

The overarching conclusion is a call for disciplined skepticism and multidisciplinary investment. A-series agents are unquestionably highly hazardous nerve agents of continuing toxicological, forensic, medical, and regulatory importance, and recent analytical advances have genuinely strengthened exposure verification and attribution. But characteristics frequently attributed to them, including exceptional persistence, rapid aging, and oxime resistance, remain supported largely by modeling and indirect observation. Progress, the authors argue, depends on maintaining a clear line between experimentally demonstrated findings and plausible but unconfirmed hypotheses, and on sustained collaboration among toxicologists, analytical chemists, clinicians, and public health agencies to close gaps in toxicokinetics, environmental fate, treatment efficacy, and long-term neurological outcomes before the next incident tests the world’s preparedness.

Subject of Research: Chemistry, toxicology, detection, and medical countermeasures of A-series Novichok nerve agents

Article Title: A-series (“Novichok”) nerve agents: Chemistry, toxicology, detection, and medical countermeasures

Article References: Nedzhib, A., Stoykova, S., Zlatkov, A., & Samnaliev, I. (2026). A-series (“Novichok”) nerve agents: Chemistry, toxicology, detection, and medical countermeasures. Pharmacia, 73, Article e205309. https://doi.org/10.3897/pharmacia.73.e205309

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e205309

Keywords: Novichok, nerve agents, organophosphorus compounds, acetylcholinesterase, chemical weapons, oximes, atropine, mass spectrometry, protein adducts, forensic toxicology, bioscavengers, decontamination